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INTRODUCTION
Human immunodeficiency virus (HIV) 
lipodystrophy is characterized by changes 
in fat distribution and increase in insulin 
resistance. A disturbance of  lipid metabolism, 
as the consequence of  viral infection, 
or the association of  virus-antiretroviral 
genetic therapy background, seems to play 
a central role in the pathogenesis of  this 
syndrome. Also insulin resistance is one of  
the earliest metabolic alterations present 
in patients with HIV and with protease 
inhibitors (PIs) therapy [1]. In the last two 
decades, PIs therapy improved survival and 
quality of  life of  HIV-infected patients. 
These patients often develop a syndrome 
characterized by peripheral lipoatrophy, 
trunk fat accumulation, and metabolic 
alterations. The causes of  this clinical 
picture are still not completely defined. 
The lipodystrophy in HIV-1 patients in 
antiretroviral treatment is associated with 
peripheral fat wasting and central adiposity, 
dyslipidemia, and insulin resistance but also 
with increase intramuscular fat accumulation, 
related to development of  the insulin 
resistance syndrome[2].
The distribution of  fat in humans is 
governed by many factors, including 
genetics, hormonal pathway in particular sex 
hormones, age, environmental factors (such 
as diet, exercise, integrators and drugs), and 
associated diseases.
FGF21 is a hormone able to determine 
some metabolic adaptations essential for 
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Recently new evidence about fibroblast growth factor 21 (FGF21) highlights the opportunities 
to use this molecule in new pharmaceutical formulations to combat type 2 diabetes and 
metabolic syndrome. It is well known that HIV is per se a condition of insulin resistance 
and in particular the patient with HIV-related lipodystrophy has a condition strictly related to 
metabolic syndrome. Lipodystrophy is associated with severe metabolic side effects, including 
dyslipidemia, hepatic insulin resistance, and lipid oxidation impairment. Research carried out 
showed that FGF21 levels were significantly increased in untreated HIV-1-infected patients 
and the increase was much marked in HIV-1-infected antiretroviral-treated patients that have 
developed lipodystrophy and in the patients with greatest metabolic alterations. FGF21 is 
expressed mainly by the liver, but also by other tissues such as the thymus, adipose tissue, 
and skeletal muscle. Therefore, many researchers have considered the investigation of 
possible variations of FGF21 in patients with significant alterations in body composition both 
in regard to fat mass and lean mass. In the light of the possible interactions between FGF21 
and metabolic syndrome, it seems interesting to evaluate the implication of this hormone 
in patients with HIV-related lipodystrophy who have a severe metabolic picture of insulin 
resistance with important alterations in body composition.
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the homeostasis of  our body. In particular, the ability 
to increase lipid oxidation from the liver, the stimulus to 
gluconeogenesis and ketogenesis appear as the fundamental 
mechanisms during the fasting period[3].
FGF21 is also able to bind to receptors in the hypothalamus, 
producing an increase in energy expenditure and 
improvement of  insulin sensitivity. In humans, it appears 
that the transport of  FGF21 in the central nervous system 
is mediated by transporters given the size of  this protein[4]. 
A critical metabolic feature of  FGF21 is its capacity to 
sensitize insulin action in vivo[5].
As metabolic modulator, FGF21 seems to play an 
important role in lipolysis during starvation, in fatty acid 
oxidation and in promoting ketogenesis[6,7]. FGF21 seems 
to be able to increase the insulin receptors in the liver, 
resulting in an improvement of  insulin sensitivity in toto 
and, in adipose tissue, appears to inhibit the lipolysis in 
adipocytes with consequent reduction of  circulating fatty 
acids. These two mechanisms cause an improvement in 
insulin sensitivity in humans.[8,9]
HIV AND LIPODYSTROPHY
In HIV patients on antiretroviral therapy with protease 
inhibitors, alterations in glucose and lipid metabolism 
are well known [1]. Along with the metabolic alterations 
morphological changes often accompany these individuals 
in particularly alteration the redistribution of  the fat tissue.
In particular, in this syndrome, there is a severe 
lipoatrophy[10]. Lipoatrophy is primarily subcutaneous 
fat loss. Fat deposition in patients with HIV occurs 
in the visceral depot (intra-abdominally), breasts, and 
dorsocervical area of  the neck. Sometimes, some patients 
have fat deposits in the form of  lipomas. The term “HIV-
associated adipose redistribution syndrome” has been used 
to define a distinct subset of  general lipodystrophy, which 
is characterized by the abnormal accumulation of  visceral 
adipose tissue, with or without comorbid lipoatrophy and 
metabolic abnormalities such as alteration of  lipid profile 
or insulin resistance [11].
In fact, the term “lipodystrophy syndrome” in association 
with HIV was introduced to describe a complex medical 
picture, including an apparent abnormal fat redistribution 
and metabolic alterations present in HIV patients receiving 
protease inhibitor therapy.
The adipose tissue in HIV patients with lipodystrophy is 
reduced in some locations with a buildup in other, and 
there is a reduction of  the tissue under the skin on the face 
and limbs with a simultaneous increase in visceral fat[12]. In 
patients with HIV lipodystrophy, there are alterations in 
body composition that remind, in part, those in patients 
with Cushing’s syndrome in which there is an increase in 
visceral fat and a decrease of  subcutaneous fat. Although 
there is not a situation of  real hypercorticism in HIV 
patients[13], hypertrophic changes consist of  excess fat 
deposition, common around the abdominal region, but 
also in the neck, in the supraclavicular fossae, or in the 
subcutaneous tissues of  the posterior neck, between the 
scapulae. Atrophic changes consist of  subcutaneous fat 
atrophy in the legs, buttocks, arms, and nasolabial and malar 
fat pads. The cosmetically disfiguring changes that occur 
with lipodystrophy may have a significant impact on quality 
of  life and relational activities[14]. Dyslipidemia was reported 
Figure 1: Morphological and metabolic alterations in patients with HIV-related lipodystrophy. The increase of insulin resistance, decrease of lipid oxidation, and redistribution 
of fat tissue has the capacity to increase the values of plasma FGF21. Therefore, this protein could be a good marker for the development and monitoring of lipodystrophy 
in HIV-infected patients. HIV: human immunodeficiency virus; FGF21: fibroblast growth factor 21; PIs: protease inhibitors. 
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in HIV-infected individuals regardless of  drug therapy[15]. 
PIs therapy of  HIV-infected individuals was associated with 
increased total cholesterol, non-HDL-C, triglyceride, IDL, 
and VLDL cholesterol. The increased VLDL levels were 
due to increased concentrations of  large VLDL particles, 
which include chylomicron remnants. Furthermore, the 
individuals receiving PIs therapy were shown to have 
altered parameters of  endothelial dysfunction[16].
Today, unfortunately, there are very few effective treatments 
to subvert the picture of  lipodystrophy in more severe 
forms that affect patients with HIV. Several forms 
of  plastic surgery have been adopted in patients with 
faciallipoatrophy[17]. Other therapies, including implants, 
have been used anecdotally in other body sites[18].
FGF21, METABOLISM, AND 
LIPODYSTROPHY
FGF21 is classified as fibroblast growth factor because it 
is very similar structurally to this category of  proteins but, 
in vivo, seems to have no ability to stimulate cell growth. 
FGF21 seems to act primarily on adipose tissue, liver, and 
pancreas. This protein has endocrine actions on different 
target organs producing important metabolic changes[7].
In particular, it plays a key role in activating mechanisms 
of  homeostasis during fasting to keep glucose levels within 
the normal range[5]. Therefore it increases gluconeogenesis, 
ketogenesis, and fatty acid oxidation [6]. Also it seems to 
be involved in the control of  blood glucose by increasing 
insulin sensitivity[3,5].
FGF21 is a powerful catabolic protein that is capable of  
potently inducing energy expenditure, thus leading to a 
negative whole-body energy balance[19]. It seems clear 
today that FGF21 acts in synergy with other hormones 
with metabolic action as insulin, glucagon, leptin, 
glucagon-like peptide, adiponectin, growth hormone, 
glucagon-like peptide 1 (GLP1), and insulin-like growth 
factor 1 (IGF1) and then it seems logical to think of  a 
potential therapeutic role in the metabolic syndrome or 
in overt diabetes[20].
In an interesting study performed on the animal model, the 
authors demonstrates that both liver mRNA expression and 
serum level of  “anti-diabetic factor” FGF21 are markedly 
up-regulated in lipodystrophic A-ZIP F-1 mice[21].
Unfortunately, most of  the studies on the action of  FGF21 
were performed in vitro or in animal models, particularly 
in murine and nonhuman primate models.
Only two FGF21 analog are study in humans[22,23] as been 
performed and the results of  these studies shown a decrease 
of  body weight, decrease of  insulin resistance, decrease of  
triglycerides, and LDL cholesterol with increase of  HDL.
FGF21 can act on brown adipose tissue (BAT) as an 
autocrine, paracrine, and endocrine agent, activating BAT 
thermogenesis[24].
In the past, various measures have been proposed in both 
pharmacology and lifestyle to improve the metabolic and 
body fat distribution in patients with lipodystrophy.
Figure 2: In patients with HIV lipodystrophy alterations of lipid metabolism appear as central in the development of this syndrome, in particular the increase of circulating 
fatty acids causes a deposition of lipids in the liver, intramuscular and in the island of Langerhans with a consequent increase of insulin resistance. This process could be 
countered by the use of FGF21 analogs. HIV: human immunodeficiency virus; FGF21: fibroblast growth factor 21; PIs: protease inhibitors; FFA: free fatty acid.
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In particular, the modification of  lifestyle (3 h of  physical 
activity at moderate intensity per-week) was studied in 
patients with HIV-related lipodystrophy with significant 
improvement of  metabolic picture after six months of  
intervention, and, in this study, it was concluded that 
intensive lifestyle modification improved important 
cardiovascular risk indices in HIV patients with the 
metabolic syndrome[25].
In another study performed by our group, it has been 
highlighted that in patients with lipodystrophy in 
acquired immune deficiency syndrome, eight months 
of  l-acetylcarnitine treatment increased lipid oxidation, 
decreased intramyocellular triglyceride content, and 
induced a more physiological distribution of  fat tissue[26]. In 
2010, a careful meta-analysis of  the effects of  metformin 
in this patient population revealed favorable impacted 
outcomes consistent in significant reductions in fasting 
insulin, fasting triglycerides, body mass index, and waist-
to-hip ratio[27]. In a recent paper, it has been demonstrated 
that FGF-21 mRNA expression is increased in skeletal 
muscle in patients with HIV-related lipodystrophy and that 
FGF-21 mRNA expression in muscle is associated with 
decreased limb fat mass, increased waist-to-hip ratio, and 
increased triglycerides[28].
Another well-conducted study found highly significant 
correlation between FGF21 levels and indicators of  altered 
fat distribution in lipodystrophy and a positive relationship 
between FGF21 levels and the extent of  lipodystrophy[29].
On the contrary, there is no strict correlation between 
FGF21 levels and fat mass in obese patients. In particular, 
the association of  serum FGF21 levels with BMI and fat 
percentage is weaker than other adipokines predominantly 
produced from adipose tissue, such as leptin[30].
POSSIBLE ROLE OF FGF21 IN 
ASSESSING THE DEGREE OF 
LIPODYSTROPHY
The role of  adipocytokines and of  other hormones in the 
pathogenesis of  HIV-associated lipodystrophy is still not 
enough understood. In particular, in our review, we focused 
attention on FGF21, which is expressed mainly by the liver, 
but also by other tissues such as adipose tissue[31]. Moreover, 
adipose tissue showed a large high expression of  FGF 
receptor 1[32] and emerged as a strong candidate to represent 
a predominant FGF21 target tissue. This new evidence 
about FGF21 highlights the opportunities to target this 
molecule for new pharmaceutical formulations to combat 
type 2 diabetes and metabolic syndrome[20] and that a rise 
in circulating FGF21 has been proposed as a predictor of  
the development of  the metabolic syndrome and type 2 
diabetes mellitus[33]. We decided to propose this hormone 
as a marker of  metabolic and morphological alterations 
in the patient with HIV-related lipodystrophy in order to 
monitor the efficacy of  the proposed interventions (drugs, 
modification of  lifestyle, and different supplements).
The study performed by Domingo and coworkers shows 
that the indices of  fat distribution (waist-to-hip ratio and 
trunk/apendicular fat ratio) are closely correlated with the 
values of  FGF21 in subjects with HIV-related lipodystropy. 
In the same study, it is emphasized that the positive 
correlation between FGF21 and HOMA-IR, triglycerides, 
and LDL cholesterol. It seems clear that the value of  
FGF21 in this group of  patients could be employed on a 
large scale in order to assess the starting point of  start of  
this complication and then monitoring the effectiveness 
of  intervention proposed through dosing FGF21 over 
time. The opportunity to use the same assay to monitor 
the metabolic and morphologic distribution of  fat linked 
to lipodystrophy looks very interesting and promising.
More studies are needed to confirm this trend highlighted 
by the study of  Domingo[29] but the presuppositions seem 
encouraging.
CONCLUSION
The hormone FGF21 seems to have a fundamental role 
in the modulation of  the metabolism in humans also 
is largely produced by adipose tissue and it performed 
various actions directly on adipose tissue[34]. Given the 
severe metabolic and morphological alterations of  adipose 
tissue in HIV-related lipodystrophy, FGF21 appears be 
an ideal candidate to assess the susceptibility of  a patient 
with HIV to develop lipodystrophy. At the same time, 
this protein can be a promising marker for assessing the 
effectiveness of  pharmacological and other interventions 
on lipodystrophy. At present, to confirm this hypothesis, 
it will require prospective studies on a large number of  
patients in order to determine the real role of  FGF21 
as a marker of  lipodystrophy in HIV patients. The big 
pharmacological efforts to get the identification of  a drug 
with similar action of  FGF21could open new perspectives 
in the treatment of  HIV-related lipodystrophy. 
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